Latest Regulatory Risks News

Page 1 of 30
DPM Metals reported US$610.1 million of nine-month free cash flow and expects to finish 2026 at the high end of production guidance. But the Vareš mine’s legal foundation remains under review in Bosnia and Herzegovina, creating a sharp contrast between operational momentum and regulatory risk.
Maxwell Dee
Maxwell Dee
13 Nov 2026
Eversource Energy narrowed its 2026 recurring earnings guidance after third-quarter GAAP profit fell, while a $26.5 billion investment plan and unresolved regulatory exposures shape the utility’s next phase. The guidance midpoint rose to US$4.66 per share despite lower year-to-date reported earnings.
Maxwell Dee
Maxwell Dee
5 Nov 2026
Helix Resources says it learned of the British Columbia court order setting aside its Gold Basin joint venture on the morning of 14 October, after Canex had published the ruling. The company told ASX it considers the disclosure timely and remains compliant with Listing Rule 3.1.
Maxwell Dee
Maxwell Dee
4 Nov 2026
AMD delivered a record fiscal third quarter as Data Center revenue nearly doubled year over year, pushing total revenue up 45% to US$13.4 billion. The company expects another sharp acceleration in the December quarter, but gaming weakened and customer warrant revaluations distorted GAAP earnings.
Victor Sage
Victor Sage
4 Nov 2026
Entergy delivered a sharp rise in third-quarter earnings, while narrowing its 2026 adjusted EPS guidance and raising its quarterly dividend. Stronger electricity sales, regulatory recovery and construction-related returns drove the result, although rising debt and capital spending remain part of the equation.
Maxwell Dee
Maxwell Dee
3 Nov 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.
Victor Sage
Victor Sage
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026
EQT Holdings delivered strong growth from its continuing businesses in FY26, but a superannuation exit, litigation and takeover uncertainty left group profit and dividends lower. The company says discussions with BGH Capital and TPG Global remain open, while targeting completion of the superannuation exit by the end of 2027.
Claire Turing
Claire Turing
21 Oct 2026
Dusk Group has carried its FY26 momentum into the new financial year, with like-for-like sales up 7.2% in the first 15 weeks despite operating six fewer stores. The home-fragrance retailer is now preparing a tightly controlled South African launch while an unresolved ACCC court case remains a material complication.
Logan Eniac
Logan Eniac
16 Oct 2026
WiseTech Global’s FY26 annual report charts a year of extraordinary expansion, with revenue up 79% after the e2open acquisition and underlying EBITDA up 56%. But the stronger earnings base comes with heavier debt, a major workforce reset and unresolved regulatory risks.
Sophie Babbage
Sophie Babbage
13 Oct 2026

Browse the archive

Full archive